Bradley J.G. Larson, MD joined the cancer care team of Northwest Georgia Oncology Centers, P.C. (NGOC) upon completion of his Fellowship at the University of Florida in 2004.
Dr. Larson is actively involved in cancer research and clinical trials to find a cancer cure and provide his patients with the most advanced cancer treatment available in Georgia.
Dr. Larson provides patient-centered cancer care at NGOC’s Carrollton Cancer Center and Bremen Cancer Center.
| Personal Data | Birthplace: Minneapolis, MN |
| Undergraduate Education | BS with distinction, Zoology, 1993 University of Wisconsin-Madison |
| Medical Education | Doctor of Medicine University of Wisconsin-Madison Medical School 1993 - 1997 Madison, WI |
| Postdoctoral Training | INTERNSHIP AND RESIDENCY Internal Medicine University of Florida, Gainesville, FL 1997 - 2000 Chief Resident, Internal Medicine, University of Florida 2000-2001 FELLOWSHIP Clinical Hematology and Oncology University of Florida, Gainesville, FL 2001 - 2004 |
| Board Certification | American Board of Internal Medicine, Medical Oncology, 2004 American Board of Internal Medicine, Hematology, Board Eligible |
| Medical Licensure | State of Georgia, 2004 (Active) |
| Professional Societies | Medical Association of Georgia Georgia Society of Clinical Oncology |
| Honors | Election to College of Letters and Sciences Dean’s List, 1989, 1991 Peter and Emily Lound Scholarship, 1993 Recipient of Letter of Commendation for Academic Achievement, 1993, 1996 UW Medical Student Association Leadership Award, 1994, 1995 Student Leadership Award, 1995 “Resident of the Month” Department of Emergency Medicine, 1999 Senior Resident Teaching Award, 1999 |
| Publications | PUBLICATIONS: Larson B, Waples J, Lynch J. A phase II study of patients with relapsed or refractory indolent non-Hodgkin’s lymphoma treated with Gemcitabine. American Journal of Clinical Oncology 28(2):165-168, 2005. Larson B, Zumberg M, Kitchens C. A Feasibility Study of Continuing Dose- Reduced Warfarin for Invasive Procedures in Patients with High Thromboembolic Risk. Chest 127: 922-927, 2005. Smock AL, Larson B, Brown C, Conti CR. Echocardiographic assessment of left ventricular function early after Q-wave Myocardial Infarction predicts thirty day prognosis. Clinical Cardiology 24(3): 191-195, 2001. ABSTRACTS: Larson B, Zumberg M, Kitchens C. A feasibility study of continuing dose-related warfarin for major surgery in patients with high thromboembolic risk. ASH Poster presentation; Abtract #1148, 2003 “CD 23 status predicts survival in atypical CLL”. ASH supplement, Astract 2000. |
| Major Research Interests | Clinical Trials (Oncology & Hematology) |